Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Jason Butch Biography and Net Worth

Insider of Agile Therapeutics

Mr. Jason Butch is a Chief Accounting Officer at Agile Therapeutics, Inc.

What is Jason Butch's net worth?: The estimated net worth of Jason Butch is at least $28,149.42 as of March 29th, 2021. Mr. Butch owns 18,642 shares of Agile Therapeutics stock worth more than $28,149 as of November 26th. This net worth approximation does not reflect any other assets that Mr. Butch may own. Learn More about Jason Butch's net worth.
How do I contact Jason Butch?: The corporate mailing address for Mr. Butch and other Agile Therapeutics executives is 101 POOR FARM ROAD, PRINCETON NJ, 08540. Agile Therapeutics can also be reached via phone at (609) 683-1880 and via email at [email protected]. Learn More on Jason Butch's contact information.
Has Jason Butch been buying or selling shares of Agile Therapeutics?: Jason Butch has not been actively trading shares of Agile Therapeutics during the last ninety days. Most recently, on Monday, March 29th, Jason Butch bought 1,358 shares of Agile Therapeutics stock. The stock was acquired at an average cost of $1.99 per share, with a total value of $2,702.42. Following the completion of the transaction, the insider now directly owns 18,642 shares of the company's stock, valued at $37,097.58. Learn More on Jason Butch's trading history.
Who are Agile Therapeutics' active insiders?: Agile Therapeutics' insider roster includes Alfred Altomari (CEO), Jason Butch (Insider), and Dennis Reilly (CFO). Learn More on Agile Therapeutics' active insiders.

Jason Butch Insider Trading History at Agile Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/29/2021	Buy	1,358	$1.99	$2,702.42	18,642
3/26/2021	Buy	8,642	$2.01	$17,370.42	18,642

Jason Butch Buying and Selling Activity at Agile Therapeutics

Agile Therapeutics Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $1.51

$1.51

$1.52

50 Day Range

MA: $1.49

$1.43

$1.51

2 Week Range

Now: $1.51

$0.20

$2.63

Volume

120,900 shs

Average Volume

352,864 shs

Market Capitalization

$10.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58